HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

被引：0
|
作者：
Miller, Kathy
Cortes, Javier
Hurvitz, Sara A.
Krop, Ian E.
Tripathy, Debu
Verma, Sunil
Riahi, Kaveh
Reynolds, Joseph G.
Wickham, Thomas J.
Molnar, Istvan
Yardley, Denise A.
机构：
[1] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[2] Vall DHebron Univ Hosp, Barcelona, Spain
[3] UCLA Healthcare Hematol Oncol Breast Oncol Progra, Santa Monica, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[7] Merrimack Pharma, Cambridge, MA USA
[8] Merrimack Pharmaceut Inc, Cambridge, MA USA
[9] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps641
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS641
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).
    Miller, Kathy
    Cortes, Javier
    Hurvitz, Sara A.
    Krop, Ian E.
    Tripathy, Debu
    Verma, Sunil
    Dionne, Michelle
    Campbell, Karen
    Reynolds, Joseph G.
    Wickham, Thomas J.
    Molnar, Istvan
    Yardley, Denise A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)
    Miller, K.
    Cortes, J.
    Hurvitz, S. A.
    Krop, I. E.
    Tripathy, D.
    Verma, S.
    Riahi, K.
    Reynolds, J. G.
    Wickham, T.
    Molnar, I.
    Yardley, D. A.
    [J]. CANCER RESEARCH, 2016, 76
  • [3] HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1
    Cortes Castan, J.
    Verma, S.
    Hurvitz, S.
    Krop, I. E.
    Tripathy, D.
    Yardley, D. A.
    Dionne, M.
    Reynolds, J.
    Wickham, T.
    Molnar, I.
    Miller, K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe
    Miller, Kathy
    Cortes, Javier
    Hurvitz, Sara A.
    Krop, Ian E.
    Tripathy, Debu
    Verma, Sunil
    Riahi, Kaveh
    Yardley, Denise A.
    [J]. CANCER RESEARCH, 2015, 75
  • [5] HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer
    Miller, Kathy
    Cortes, Javier
    Hurvitz, Sara A.
    Krop, Ian E.
    Tripathy, Debu
    Verma, Sunil
    Riahi, Kaveh
    Reynolds, Joseph G.
    Wickham, Thomas J.
    Molnar, Istvan
    Yardley, Denise A.
    [J]. BMC CANCER, 2016, 16
  • [6] HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
    Kathy Miller
    Javier Cortes
    Sara A. Hurvitz
    Ian E. Krop
    Debu Tripathy
    Sunil Verma
    Kaveh Riahi
    Joseph G. Reynolds
    Thomas J. Wickham
    Istvan Molnar
    Denise A. Yardley
    [J]. BMC Cancer, 16
  • [7] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Al Rabadi, Luai S.
    Cook, Madeline M.
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi, I
    [J]. BMC CANCER, 2021, 21 (01)
  • [8] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Luai S. Al Rabadi
    Madeline M. Cook
    Andy J. Kaempf
    Megan M. Saraceni
    Michael A. Savin
    Zahi I. Mitri
    [J]. BMC Cancer, 21
  • [9] Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study
    Kojima, Yasuyuki
    Yoshie, Reiko
    Kawamoto, Hisanori
    Shimo, Arata
    Uejima, Tomoko
    Iwatani, Tsuguo
    Motoyoshi, Ai
    Kanemaki, Yoshihide
    Boku, Narikazu
    Tsugawa, Koichiro
    [J]. ONCOLOGY, 2019, 96 (06) : 309 - 317
  • [10] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    [J]. ONCOLOGIE, 2013, 15 (02) : 126 - 127
12345